Tags |
|
|
Links |
|
|
Cases - In Division There is Opportunity
Unless companies adopt an holistic approach to security that focuses on buildi
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
ng and fostering a culture of honesty and integrity, GAP’s will appear in thei
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
defenses and in their ability to perform their mission of selling their produ
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
ts and services. Once GAP’s are exposed, they can be exploited for the persona
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
gain of the individual(s) exposing them. Once this occurs, the only question
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
remaining will be; can you cope with the crisis being caused and to what exten
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
is "damage control" required. Insurium has the solution www.insurium.com
In
In
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
rder, to adequately protect your corporate assets (People, Property, Income an
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
Reputation), companies need to understand what they are exposed to. This requ
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ires a corporate understanding that integrates business and technological pers
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ectives. When we speak of risks associated with assets, we need to evaluate al
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
risks and incorporate these risks into our strategic and crisis planning. Imp
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
ementing prevention strategies will ultimately reduce the risk of an occurrenc
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
e. Occurrences could range from minor to major occurrences inhibiting a compan
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
from continuing its mission.
The risk of disaster and mismanagement are inhe
The risk of disaster and mismanagement are inhe
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
ent in the corporate world and therefore, upper management should be responsib
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
e to ensure that the corporation is exercising the necessary amount of "duty o
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
f trust" and "duty of care". Reasonable efforts to investigate and become info
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
med about the condition of the corporation, its assets and the conduct of its
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
ffairs would be seen as a responsibility "prudent" business men would exercise
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.cases.org.ua/article/1234/cases-In-Division-There-is-Opportunity.html">In Division There is Opportunity</a>
BB link (for phorums):
[url=http://www.cases.org.ua/article/1234/cases-In-Division-There-is-Opportunity.html]In Division There is Opportunity[/url]
Related Articles:
Do You Need an MBA to Run a Successful Business, or Vision?
Bookmark it:
|